DiaMedica Therapeutics Advances with Positive Trials and Funding

Diamedica Therapeutics ( (DMAC) ) has released its Q2 earnings. Here is a breakdown of the information Diamedica Therapeutics presented to its investors.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious ischemic diseases, including preeclampsia, fetal growth restriction, and acute ischemic stroke. The company is pioneering the use of DM199, a synthetic form of the KLK1 protein, as a potential treatment solution.

In its latest earnings report, DiaMedica Therapeutics highlighted significant progress in its clinical trials and financial positioning. The company reported positive interim data from its Phase 2 study of DM199 in preeclampsia, alongside a successful $30 million private placement, which extends its cash runway into the second half of 2027.

Key financial metrics from the second quarter of 2025 include a net loss of $7.7 million, an increase from $5.1 million in the same period last year, driven by higher research and development expenses. The company also reported a proforma cash balance of $60 million following the recent private placement, which is expected to support upcoming clinical milestones.

Strategically, DiaMedica is advancing its ReMEDy2 Phase 2/3 trial for acute ischemic stroke, with interim data expected in 2026. The company also announced its inclusion in the Russell 2000 and 3000 indexes, enhancing its visibility among investors. Additionally, the appointment of Dr. Julie Krop as Chief Medical Officer is expected to bolster its clinical development efforts.

Looking ahead, DiaMedica remains focused on advancing its DM199 candidate through clinical trials and regulatory processes, with the aim of addressing unmet medical needs in ischemic diseases. The company’s robust financial position and strategic initiatives position it well for continued progress in its therapeutic pipeline.